Chemical Reduction of Oxidized Human Lymphocytes Inhibits Interleukin 2 Production but Not Induction of Interleukin 2 Responsiveness

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 1984 Aug 1

PMID 6382260

Citations 1

Authors

E Roffman

B Sredni

A Smolinsky

M Wilchek

Affiliations

Soon will be listed here.

Abstract

Treatment with neuraminidase (NA) plus galactose oxidase (GalOxase) does not cause stimulation of human thymocytes. However, stimulation can be achieved by addition of exogenous interleukin 2 (IL-2). The IL-2-induced stimulation was inhibited with anti-Tac antibody, indicating that NA/GalOxase-oxidized cells can serve as inducers of functional IL-2 receptors on IL-2-responding T cells. The induction of IL-2 receptors by the oxidized cells was not inhibited by subsequent reduction with borohydride, since the cells could still be stimulated with IL-2. The presence of IL-2 receptors was also confirmed by flow cytometry using indirect immunofluorescence. Peripheral blood lymphocytes can be stimulated by NA/GalOxase treatment, and the conditioned medium from this treatment can support the growth of an IL-2-dependent line. This stimulation can be inhibited with borohydride and restored with IL-2. The conditioned medium derived from the borohydride-reduced cells cannot support the growth of the IL-2-dependent line, indicating that borohydride inhibits the oxidation-induced IL-2 production. The results suggest that NA/GalOxase-oxidized sites can be modified chemically without losing the potential to induce IL-2 receptors.

Citing Articles

Signaling Response to Transient Redox Stress in Human Isolated T Cells: Molecular Sensor Role of Syk Kinase and Functional Involvement of IL2 Receptor and L-Selectine.

Secchi C, Orecchioni M, Carta M, Galimi F, Turrini F, Pantaleo A Sensors (Basel). 2020; 20(2).

PMID: 31947584 PMC: 7013990. DOI: 10.3390/s20020466.

References

Novogrodsky A, Gery I . Enhancement of mouse thymus cells response to periodate treatment by a soluble factor. J Immunol. 1972; 109(6):1278-81. View

Henderson L, Hewetson J, Hopkins 3rd R, Sowder R, Neubauer R, Rabin H . A rapid, large scale purification procedure for gibbon interleukin 2. J Immunol. 1983; 131(2):810-5. View

OBRIEN R, Parker J, Paolilli P, Steiner J . Periodate-induced lymphocyte transformation. IV. Mitogenic effect of NaIO4 treated lymphocytes upon autologous lymphocytes. J Immunol. 1974; 112(5):1884-90. View

Dixon J, OBRIEN R, Parker J . Periodate-induced lymphocyte transformation. V. Inhibition of periodate-induced transformation of human peripheral lymphocytes with aldehyde-blocking agents. Exp Cell Res. 1975; 96(2):383-7. DOI: 10.1016/0014-4827(75)90271-2. View

OBRIEN R, Parker J . Oxidation-induced lymphocyte transformation. Cell. 1976; 7(1):13-20. DOI: 10.1016/0092-8674(76)90250-6. View

Gillis S, Ferm M, Ou W, Smith K . T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol. 1978; 120(6):2027-32. View

Ravid A, Novogrodsky A, Wilchek M . Grafting of triggering sites onto lymphocytes: requirement of multivalency in the stimulation of dinitrophenyl-modified thymocytes by anti-dinitrophenyl antibody. Eur J Immunol. 1978; 8(5):289-94. DOI: 10.1002/eji.1830080502. View

Reisner Y, Biniaminov M, Rosenthal E, Sharon N, Ramot B . Interaction of peanut agglutinin with normal human lymphocytes and with leukemic cells. Proc Natl Acad Sci U S A. 1979; 76(1):447-51. PMC: 382957. DOI: 10.1073/pnas.76.1.447. View

Novogrodsky A, Suthanthiran M, Saltz B, Newman D, RUBIN A, STENZEL K . Generation of a lymphocyte growth factor by treatment of human cells with neuraminidase and galactose oxidase. J Exp Med. 1980; 151(3):755-60. PMC: 2185798. DOI: 10.1084/jem.151.3.755. View

10.

Larsson E, Coutinho A . Mechanism of T cell activation. I. A screening of "step one" ligands. Eur J Immunol. 1980; 10(2):93-9. DOI: 10.1002/eji.1830100205. View

11.

Smith K . T-cell growth factor. Immunol Rev. 1980; 51:337-57. DOI: 10.1111/j.1600-065x.1980.tb00327.x. View

12.

Loor F . Plasma membrane and cell cortex interactions in lymphocyte functions. Adv Immunol. 1980; 30:1-120. DOI: 10.1016/s0065-2776(08)60194-7. View

13.

Rabin H, Hopkins 3rd R, Ruscetti F, Neubauer R, Brown R, Kawakami T . Spontaneous release of a factor with properties of T cell growth factor from a continuous line of primate tumor T cells. J Immunol. 1981; 127(5):1852-6. View

14.

Piantelli M, Lauriola L, Maggiano N, Ranelletti F, Musiani P . Role of interleukins 1 and 2 on human thymocyte mitogen activation. Cell Immunol. 1981; 64(2):337-49. DOI: 10.1016/0008-8749(81)90485-8. View

15.

Leonard W, Depper J, Uchiyama T, Smith K, Waldmann T, Greene W . A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptor. Nature. 1982; 300(5889):267-9. DOI: 10.1038/300267a0. View

16.

Walker C, Kristensen F, Bettens F, DEWECK A . Lymphokine regulation of activated (G1) lymphocytes. I. Prostaglandin E2-induced inhibition of interleukin 2 production. J Immunol. 1983; 130(4):1770-3. View

17.

Lipkowitz S, RUBIN A, STENZEL K, Novogrodsky A . Cellular and growth factor requirements for activation of human T lymphocytes by neuraminidase and galactose oxidase-treated lymphoid cells. J Immunol. 1983; 130(6):2702-7. View

18.

Depper J, Leonard W, Robb R, Waldmann T, Greene W . Blockade of the interleukin-2 receptor by anti-Tac antibody: inhibition of human lymphocyte activation. J Immunol. 1983; 131(2):690-6. View

19.

Novogrodsky A, KATCHALSKI E . Induction of lymphocyte transformation by sequential treatment with neuraminidase and galactose oxidase. Proc Natl Acad Sci U S A. 1973; 70(6):1824-7. PMC: 433605. DOI: 10.1073/pnas.70.6.1824. View